JP2006524660A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006524660A5 JP2006524660A5 JP2006505327A JP2006505327A JP2006524660A5 JP 2006524660 A5 JP2006524660 A5 JP 2006524660A5 JP 2006505327 A JP2006505327 A JP 2006505327A JP 2006505327 A JP2006505327 A JP 2006505327A JP 2006524660 A5 JP2006524660 A5 JP 2006524660A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- substituted
- chloro
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- -1 benzo [1, 3] dioxol-5-yl Chemical group 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000004802 cyanophenyl group Chemical group 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000003839 salts Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0309944 | 2003-04-30 | ||
| GB0329500A GB0329500D0 (en) | 2003-12-19 | 2003-12-19 | Organic compounds |
| GB0329505A GB0329505D0 (en) | 2003-12-19 | 2003-12-19 | Organic compounds |
| PCT/EP2004/004569 WO2004096752A1 (en) | 2003-04-30 | 2004-04-29 | Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006524660A JP2006524660A (ja) | 2006-11-02 |
| JP2006524660A5 true JP2006524660A5 (https=) | 2010-09-16 |
| JP4603531B2 JP4603531B2 (ja) | 2010-12-22 |
Family
ID=33424535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006505327A Expired - Fee Related JP4603531B2 (ja) | 2003-04-30 | 2004-04-29 | スフィンゴシン−１−ホスフェートレセプターモジュレーターとしての、アミノプロパノール誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7625950B2 (https=) |
| EP (1) | EP1622860B1 (https=) |
| JP (1) | JP4603531B2 (https=) |
| CN (1) | CN1777575B (https=) |
| AT (1) | ATE547395T1 (https=) |
| AU (1) | AU2004234066B2 (https=) |
| BR (1) | BRPI0410025A (https=) |
| CA (1) | CA2523582A1 (https=) |
| ES (1) | ES2383298T3 (https=) |
| MX (1) | MXPA05011596A (https=) |
| WO (1) | WO2004096752A1 (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7241790B2 (en) | 2002-07-30 | 2007-07-10 | University Of Virginia Patent Foundation | Compounds active in spinigosine 1-phosphate signaling |
| GB0313612D0 (en) * | 2003-06-12 | 2003-07-16 | Novartis Ag | Organic compounds |
| ATE449069T1 (de) | 2003-08-28 | 2009-12-15 | Novartis Pharma Gmbh | Aminopropanolderivate |
| US7638637B2 (en) | 2003-11-03 | 2009-12-29 | University Of Virginia Patent Foundation | Orally available sphingosine 1-phosphate receptor agonists and antagonists |
| GB0329498D0 (en) * | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
| JP5315611B2 (ja) | 2004-06-23 | 2013-10-16 | 小野薬品工業株式会社 | Ｓ１ｐ受容体結合能を有する化合物およびその用途 |
| US7781617B2 (en) | 2004-07-16 | 2010-08-24 | Kyorin Pharmaceutical Co., Ltd | Effective use method of medicaments and method of preventing expression of side effect |
| MX2007001661A (es) | 2004-08-13 | 2007-04-23 | Praecis Pharm Inc | Metodos y composiciones para modular la actividad del receptor de esfingosina -1 fosfato (sip). |
| EP1806338B1 (en) | 2004-10-12 | 2016-01-20 | Kyorin Pharmaceutical Co., Ltd. | Process for producing 2-amino-2-[2-[4-(3-benzyloxy-phenylthio)-2-chlorophenyl[ethyl]-1,3-propanediol hydrochloride and hydrates thereof. and intermediates the production thereof |
| US7754703B2 (en) | 2005-02-14 | 2010-07-13 | University Of Virginia Patent Foundation | Cycloalkane-containing sphingosine 1-phosphate agonists |
| GB0513431D0 (en) | 2005-06-30 | 2005-08-10 | Kherion Technology Ltd | Prophylactic compositions and uses |
| PL1932522T3 (pl) * | 2005-10-07 | 2012-09-28 | Kyorin Seiyaku Kk | Środek terapeutyczny do leczenia choroby wątroby zawierający jako składnik czynny pochodną 2-amino-1,3-propanodiolu |
| BRPI0619894B8 (pt) | 2005-12-15 | 2021-05-25 | Mitsubishi Tanabe Pharma Corp | composto de amina e composição farmacêutica |
| JP2009528274A (ja) | 2006-01-27 | 2009-08-06 | ユニバーシティ オブ バージニア パテント ファンデーション | 神経因性疼痛の治療法 |
| TWI389683B (zh) * | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
| JP2009526073A (ja) | 2006-02-09 | 2009-07-16 | ユニバーシティ オブ バージニア パテント ファンデーション | 二環式スフィンゴシン−１−リン酸受容体アナログ |
| US8097644B2 (en) | 2006-03-28 | 2012-01-17 | Allergan, Inc. | Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist |
| JP5140593B2 (ja) | 2006-08-08 | 2013-02-06 | 杏林製薬株式会社 | アミノアルコール誘導体及びそれらを有効成分とする免疫抑制剤 |
| CA2659598A1 (en) | 2006-08-08 | 2008-02-14 | Kyorin Pharmaceutical Co., Ltd. | Amino phosphate derivative and s1p receptor modulator having same as an active ingredient |
| AU2007323557A1 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
| JP2010510249A (ja) | 2006-11-21 | 2010-04-02 | ユニバーシティ オブ バージニア パテント ファンデーション | スフィンゴシン＝１−燐酸アゴニスト活性を有するテトラリンアナログ |
| CA2669104A1 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
| US8524917B2 (en) | 2007-01-11 | 2013-09-03 | Allergan, Inc. | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity |
| JP5341754B2 (ja) * | 2007-06-14 | 2013-11-13 | 田辺三菱製薬株式会社 | アミン化合物及びその医薬用途 |
| BRPI0817397A2 (pt) | 2007-09-24 | 2015-04-07 | Allergan Inc | Compostos indol contendo grupos arila ou heteroarila com atividade biológica do receptor de esfingosina-1-fosfato (sip) |
| TW200946105A (en) | 2008-02-07 | 2009-11-16 | Kyorin Seiyaku Kk | Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient |
| JP2011519938A (ja) | 2008-05-08 | 2011-07-14 | アラーガン インコーポレイテッド | 治療上有効な置換１，７−ジフェニル−１，２，３，５，６，７−ヘキサヒドロピリド［３，２，１−ｉｊ］キノリン化合物 |
| US8143291B2 (en) | 2008-05-09 | 2012-03-27 | Allergan, Inc. | Indole compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor biological activity |
| US8580841B2 (en) | 2008-07-23 | 2013-11-12 | Arena Pharmaceuticals, Inc. | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
| HRP20160890T1 (hr) | 2008-08-27 | 2016-09-23 | Arena Pharmaceuticals, Inc. | Derivati supstituirane tricikličke kiseline kao agonisti s1p1-receptora korisni u liječenju autoimunih i upalnih poremećaja |
| EP2491023B1 (en) * | 2009-10-23 | 2014-12-31 | Allergan, Inc. | Coumarin compounds as receptor modulators with therapeutic utility |
| EP2509938A1 (en) * | 2009-12-10 | 2012-10-17 | Novartis AG | Fty720 halogenated derivatives |
| JP5856980B2 (ja) | 2010-01-27 | 2016-02-10 | アリーナ ファーマシューティカルズ， インコーポレイテッド | （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス |
| CN105503882B (zh) | 2010-03-03 | 2019-07-05 | 艾尼纳制药公司 | 制备s1p1受体调节剂及其晶体形式的方法 |
| CN102260178A (zh) * | 2010-05-25 | 2011-11-30 | 中国医学科学院药物研究所 | 羟基丙二醇类衍生物、其制备方法和其药物组合物与用途 |
| PL3242666T3 (pl) | 2015-01-06 | 2025-02-17 | Arena Pharmaceuticals, Inc. | Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1 |
| BR112017027656B1 (pt) | 2015-06-22 | 2023-12-05 | Arena Pharmaceuticals, Inc. | Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo |
| MX2019009843A (es) | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales. |
| MX2019009841A (es) | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la colangitis biliar primaria. |
| CA3102136A1 (en) | 2018-06-06 | 2019-12-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
| CN112955431A (zh) | 2018-09-06 | 2021-06-11 | 艾尼纳制药公司 | 可用于治疗自身免疫性病症和炎性病症的化合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0778263B1 (en) * | 1994-08-22 | 2002-01-09 | Welfide Corporation | Benzene compound and medicinal use thereof |
| GB2309868A (en) * | 1996-01-30 | 1997-08-06 | Sony Corp | Radio receiver detects FCCH synchronising signal |
| ES2240868T3 (es) * | 1997-04-04 | 2005-10-16 | Mitsubishi Pharma Corporation | Compuesto de 2-aminopropano -1,3-diol, su uso farmaceutico e intermedios en su sintesis. |
| JP2001519808A (ja) | 1997-04-10 | 2001-10-23 | ファルマシア・アンド・アップジョン・カンパニー | ポリ芳香族抗菌組成物 |
| CA2442178A1 (en) * | 2001-03-26 | 2002-10-03 | Novartis Ag | 2-amino-propanol derivatives |
| JP2002316985A (ja) * | 2001-04-20 | 2002-10-31 | Sankyo Co Ltd | ベンゾチオフェン誘導体 |
| CA2461212C (en) * | 2001-09-27 | 2010-08-17 | Kyorin Pharmaceutical Co., Ltd. | Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same |
| DE60235900D1 (de) * | 2001-09-27 | 2010-05-20 | Kyorin Seiyaku Kk | Osuppressivum |
| CN100516024C (zh) | 2002-09-13 | 2009-07-22 | 诺瓦提斯公司 | 氨基-丙醇衍生物 |
-
2004
- 2004-04-29 CN CN2004800110595A patent/CN1777575B/zh not_active Expired - Fee Related
- 2004-04-29 ES ES04730206T patent/ES2383298T3/es not_active Expired - Lifetime
- 2004-04-29 WO PCT/EP2004/004569 patent/WO2004096752A1/en not_active Ceased
- 2004-04-29 JP JP2006505327A patent/JP4603531B2/ja not_active Expired - Fee Related
- 2004-04-29 BR BRPI0410025-5A patent/BRPI0410025A/pt not_active IP Right Cessation
- 2004-04-29 US US10/554,556 patent/US7625950B2/en not_active Expired - Fee Related
- 2004-04-29 MX MXPA05011596A patent/MXPA05011596A/es active IP Right Grant
- 2004-04-29 AT AT04730206T patent/ATE547395T1/de active
- 2004-04-29 AU AU2004234066A patent/AU2004234066B2/en not_active Ceased
- 2004-04-29 EP EP04730206A patent/EP1622860B1/en not_active Expired - Lifetime
- 2004-04-29 CA CA002523582A patent/CA2523582A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006524660A5 (https=) | ||
| JP2009507896A5 (https=) | ||
| EP1857457A3 (en) | Benzimidazole derivative and its use as AII receptor antagonist | |
| JP2010524932A5 (https=) | ||
| JP2019513778A5 (https=) | ||
| JP2008501000A5 (https=) | ||
| JP2013537203A5 (https=) | ||
| JP2009526034A5 (https=) | ||
| NO20072371L (no) | Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister | |
| JP2014516033A5 (https=) | ||
| ECSP066383A (es) | Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias | |
| JP2004516314A5 (https=) | ||
| JP2009518365A5 (https=) | ||
| ATE457988T1 (de) | A2a-adenosin-rezeptor-antagonisten | |
| JP2013507423A5 (https=) | ||
| WO2006098918A3 (en) | Substituted gamma lactams as therapeutic agents | |
| JP2014530900A5 (https=) | ||
| JP2013544860A5 (https=) | ||
| JP2013542261A5 (https=) | ||
| JP2012510957A5 (https=) | ||
| JP2013514980A5 (https=) | ||
| JP2008500999A5 (https=) | ||
| JP2012512863A5 (https=) | ||
| MX2010001020A (es) | Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas. | |
| JP2007522142A5 (https=) |